Quick Answer
BioAge Labs, Inc. reported Cash and Equivalents of $188.89 million for fiscal year 2025.
BioAge Labs, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $188.89M | -46.7% |
| 2024 | $354.35M | +1537.2% |
| 2023 | $21.64M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $215.57M | -35.5% | -2.2% |
| June 30, 2025 | $220.33M | — | -14.4% |
| March 31, 2025 | $257.49M | +48.0% | -27.3% |
| December 31, 2024 | $354.35M | +1537.2% | +5.9% |
| September 30, 2024 | $334.47M | — | +92.2% |
| March 31, 2024 | $173.99M | — | +703.9% |
| December 31, 2023 | $21.64M | — | — |
- BioAge Labs, Inc. showed a decrease of -46.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, BioAge Labs, Inc.’s cash and equivalents has grown by 772.7% (from $21.64 million to $188.89 million).
- The most recent figure is from BioAge Labs, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: